Latest / Pharmacy Podcast Network / Tariffs, Trade, and Turbulence: Navigating the Impact on Pharmacy | Pharmacy Tech Trends: PrimeRx
Transcript
- 0:05Speaker 1: You are listening to the global network of podcasters dedicated
- 0:09Speaker 1: to the pharmacy profession. Welcome to the Pharmacy Podcast Network.
- 0:27Speaker 2: We are committed to the pharmacy owner's success. PRIMRX believes
- 0:30Speaker 2: in empowering pharmacies with innovative solutions to thrive in today's
- 0:34Speaker 2: competitive landscape.
- 0:36Speaker 3: We look forward to working with.
- 0:37Speaker 2: Pharmacy owners and sharing how our solutions can contribute to
- 0:41Speaker 2: their sustained.
- 0:41Speaker 3: Profitability and growth.
- 0:43Speaker 2: Connect with us on the web by going to primarx
- 0:46Speaker 2: dot io. That's primearx dot io.
- 0:50Speaker 1: Hey there, this is Toddy. You're a founder of the
- 0:52Speaker 1: Pharmacy Podcast Network, bringing you another pharmacy podcast. Tech trends
- 0:57Speaker 1: from the team at PrimeRx and today is a necessary topic.
- 1:03Speaker 1: It's something that we definitely want more information on. I
- 1:08Speaker 1: always want to demystify things, and I like having people
- 1:13Speaker 1: in position to bring us information that we can rely
- 1:17Speaker 1: on and go back to as business owners, as pharmacy
- 1:20Speaker 1: owners and be like, Okay, this is good. At least
- 1:24Speaker 1: it gets the latest in the subject. And the subject
- 1:28Speaker 1: is the tariffs and how is a tariff going to
- 1:33Speaker 1: impact all of us? How's it going to impact the
- 1:36Speaker 1: independent community? Pharmacy and our wholesaler relationships and technology. So
- 1:40Speaker 1: today it's tariffs, trade and turbulence, navigating the impact on pharmacy.
- 1:46Speaker 1: And my guest is a returning Pharmacy Podcast Network guest,
- 1:50Speaker 1: David Kirkis. He's vice president of market at prim r Ex.
- 1:54Speaker 1: David is great to have you.
- 1:56Speaker 3: Back, Thanks Todd, great to be back with you again.
- 2:00Speaker 1: All right, so new developments surrounding pharmaceutical tariffs. We have
- 2:06Speaker 1: news that is it's fresh and if you haven't seen it,
- 2:11Speaker 1: just on the nineteenth of the month on Pharma Voice.
- 2:15Speaker 1: It's the farm of Voice publishes and it's titled Tracking
- 2:21Speaker 1: a Moving Target drugger Maker's break for looming tariff impact
- 2:26Speaker 1: and with policies and flux, companies seek to be proactive
- 2:29Speaker 1: and understand their supply chain. This is a great article.
- 2:32Speaker 1: We're going to have this in the show notes. We're
- 2:34Speaker 1: going to have a link to this article in the
- 2:36Speaker 1: show notes and definitely take a read to that. But
- 2:40Speaker 1: I want to shift it over to you first, David,
- 2:43Speaker 1: kind of just let's get some things out of the way.
- 2:46Speaker 3: Let's slow down for a second.
- 2:47Speaker 1: Like I said, I like to demystify, so right out
- 2:50Speaker 1: of the gate, let's get a brief overview of the
- 2:53Speaker 1: current state of pharmaceutical tariffs from your perspective.
- 2:58Speaker 3: Sure, yeah, it seems to be a moving target over
- 3:02Speaker 3: the last few weeks with a lot of things in
- 3:04Speaker 3: flux and uncertainty. I think for everybody potentially impacted by
- 3:09Speaker 3: pharmaceutical tariffs is top of mind right now, and how
- 3:14Speaker 3: do we react in an uncertain time is going to
- 3:17Speaker 3: be really critical over the next several months for pharmacies
- 3:20Speaker 3: and everyone else impacted across the entire drug chain in
- 3:24Speaker 3: supply chain in the US, so the proposed tariffs would
- 3:29Speaker 3: impact imported finished drugs or active pharmaceutical ingredients. This comes
- 3:35Speaker 3: from Commerce Department insights, citing national security concerns around the
- 3:41Speaker 3: excessive reliance we have in the US on foreign produced pharmaceuticals.
- 3:47Speaker 3: About ninety percent of generic drugs are manufactured abroad, primarily
- 3:52Speaker 3: in India and China, and that reliance comes with exposure.
- 3:58Speaker 3: It makes our supply chain or fragile than we'd like
- 4:01Speaker 3: it to be and exposed to global disruptions potentially. So
- 4:07Speaker 3: let's keep in mind that these tariffs have been floated
- 4:10Speaker 3: as an idea, it's a policy proposal. There's no timeline
- 4:14Speaker 3: there's really no framework and structure that we can use
- 4:19Speaker 3: to guide us at this current point, so we'll have
- 4:22Speaker 3: to continue to monitor how the administration moves forward over
- 4:26Speaker 3: the next several weeks. But subsequence to the announcement of
- 4:29Speaker 3: proposed tariffs, we also had on May twelfth, the new
- 4:33Speaker 3: executive order issued that establishes most Favored Nation pricing and
- 4:37Speaker 3: requires the US to pay no more than the lowest
- 4:40Speaker 3: price paid by peer nations for the same drugs. So
- 4:43Speaker 3: a lot of really sort of blunt macroeconomic tools that
- 4:48Speaker 3: the administration is proposing aimed primarily at bringing production back
- 4:53Speaker 3: to the US and then also lowering drug costs. I
- 4:58Speaker 3: think these are very well intended pol proposals, but potentially
- 5:02Speaker 3: very destabilizing in the short term. I think before we
- 5:06Speaker 3: move to I think it's also important to note that
- 5:12Speaker 3: drug pricing. It always mystifies me how much attention that
- 5:17Speaker 3: drug pricing commands from both politicians and media sources. Prescription
- 5:22Speaker 3: drugs account for less than ten percent of the total
- 5:24Speaker 3: US healthcare spending and provide life saving treatments. They decrease
- 5:30Speaker 3: the overall health cost of health care. There's plenty of
- 5:34Speaker 3: evidence that more utilization of drugs. Better adherence to medications
- 5:38Speaker 3: that patients are on will further decrease the overall cost
- 5:42Speaker 3: of health care. So I think it's a bit unfortunate
- 5:46Speaker 3: that pharmaceutical pricing commands as much attention as it does.
- 5:51Speaker 3: But because it does, we are all affected by these
- 5:54Speaker 3: policy decisions, and as always, pharmacy tends to find itself
- 6:00Speaker 3: in the middle and exposed in a variety of different directions.
- 6:05Speaker 1: I'm glad you mentioned that there there are we could
- 6:07Speaker 1: start slicing the pie around the impact of tariffs on
- 6:12Speaker 1: different portions of the ecosystem. And not only do companies
- 6:15Speaker 1: have to know where the products are coming from, but
- 6:18Speaker 1: they also have to determine that country of origin for
- 6:20Speaker 1: the ingredients, which is not always straightforward, and I think
- 6:24Speaker 1: of where the API was manufactured, but it can shift
- 6:29Speaker 1: to that finished dose if there's a substantial transformation, which
- 6:33Speaker 1: can occur when products contain multiple APIs, and that was
- 6:38Speaker 1: mentioned in the Farm of Voice article, and it comes
- 6:42Speaker 1: down to that supply chain disruption. So how are tariffs
- 6:46Speaker 1: how do they affect the importation importing of active pharmaceutical
- 6:51Speaker 1: ingredients and in those finished drugs.
- 6:54Speaker 3: Well, I think so tariffs in the pharmaceutical industry is new, right,
- 7:00Speaker 3: This is not traditionally the way that the United States
- 7:07Speaker 3: treats pharmaceutical manufacturers. So I think we have a couple
- 7:12Speaker 3: of things we can look at. Is the way that
- 7:14Speaker 3: tariffs have impacted other industries where they have been imposed,
- 7:18Speaker 3: and what you see in the short term is typically
- 7:22Speaker 3: increase pricing and supply disruption, and I don't see how
- 7:27Speaker 3: we would avoid either of those in a world where
- 7:32Speaker 3: you know, immediate tariffs of significant amounts are imposed on
- 7:36Speaker 3: pharmaceutical ingredients and finished products. The reason is very simple.
- 7:42Speaker 3: It's the pharmaceutical manufacturing industry exists to produce drugs and
- 7:48Speaker 3: sell them profitably wherever they're selling them, and if their
- 7:51Speaker 3: costs increase, they are going to pass those costs on
- 7:56Speaker 3: and remain profitable producing the pharmaceuticals that they're producing one
- 8:02Speaker 3: way or the other. And if that means passing on
- 8:04Speaker 3: the cost, that's going to lead to a rise in
- 8:08Speaker 3: costs for those drugs in the US in the short term.
- 8:12Speaker 3: The other potential consequence is rationalization of production lines where
- 8:19Speaker 3: lower margin products. You know, pharmaceutical manufacturers in India, for instance,
- 8:24Speaker 3: are not going to be thinking about the long term
- 8:26Speaker 3: impact on supply and availability in the US. They're thinking
- 8:30Speaker 3: about which product lines that my teams are producing are
- 8:35Speaker 3: generating the most profit for my company, and when those
- 8:38Speaker 3: product profits are impacted, they will very easily stop stop
- 8:42Speaker 3: producing drugs and shift production to others where they can,
- 8:46Speaker 3: you know, better manage the financial impacts to their own businesses. So,
- 8:52Speaker 3: and you know, think all the way down to the
- 8:54Speaker 3: pharmacy counter, what do those impacts look like. I think
- 8:58Speaker 3: it's it's a combination of generics in particularly having a
- 9:03Speaker 3: lot of volatility around pricing ye, and further enhanced by
- 9:08Speaker 3: disruptions to supply making it more difficult to find the
- 9:13Speaker 3: drugs that pharmacies need, particularly if they're shopping in a
- 9:16Speaker 3: single source. Yeah.
- 9:19Speaker 1: I also think so we want based on these tariffs,
- 9:24Speaker 1: the administration is saying, hey, we want more production happening
- 9:30Speaker 1: here at home. We want it to be from the
- 9:32Speaker 1: United States. And that's great, But to stand up a
- 9:34Speaker 1: manufacturing plant in the United States, you do need FDA approval,
- 9:39Speaker 1: And I'm wondering will the FDA expedite and start concentrating
- 9:47Speaker 1: on getting more authorization in place for manufacturers that are
- 9:52Speaker 1: like bringing things back. I think of my own you know,
- 9:57Speaker 1: my own community of of southwestern Pennsylvania. And we have
- 10:03Speaker 1: a rich source of generic creation right here in southwestern Pennsylvania,
- 10:12Speaker 1: with several industrial parks that have pharmaceutical generic manufacturers in them.
- 10:19Speaker 1: And one of them that was close in Cannonsburg, which
- 10:22Speaker 1: which moved moved overseas, and that was seven to nine
- 10:29Speaker 1: years ago. And I'm wondering does this does this create
- 10:34Speaker 1: a resurgence where they come back and and begin manufacturing again,
- 10:40Speaker 1: because they they if you think of the employee access
- 10:44Speaker 1: of a of an entire environment and of a you know,
- 10:48Speaker 1: the south western Pennsylvania region, the Pittsburgh region has this
- 10:53Speaker 1: huge source of of employees that could really jump in immediately.
- 10:57Speaker 1: But what do you think of of those other stipulations
- 11:00Speaker 1: that would that we're going to have to expedite in
- 11:04Speaker 1: order to, you know, in order to start manufacturing here
- 11:08Speaker 1: at home.
- 11:09Speaker 3: Yeah, it's certainly not something that we can ramp up
- 11:11Speaker 3: and scale to the current level of international production over
- 11:17Speaker 3: over months. It's certainly a year's long process to move
- 11:23Speaker 3: an entire industry from a foreign source to a US
- 11:27Speaker 3: based source. I think again, the intention is is very
- 11:32Speaker 3: aspirational and certainly long term the right thing to do
- 11:36Speaker 3: for the US economy and the US healthcare system as
- 11:39Speaker 3: a whole. I just think that, you know, that gap
- 11:43Speaker 3: between where we are now and where we would like
- 11:45Speaker 3: to be is very difficult to cross. It's a very
- 11:50Speaker 3: complex industry, and it's going to be resisted from a
- 11:56Speaker 3: lot of different avenues. I think you're going to see
- 11:59Speaker 3: litigation slowing processes and potentially turning this into something that
- 12:04Speaker 3: could linger for some time before we arrive at that
- 12:09Speaker 3: sort of nirvana state where the US is reliant on
- 12:12Speaker 3: itself to supply pharmaceuticals. So yeah, I think going back
- 12:19Speaker 3: to where I started, I think uncertainty is going to
- 12:22Speaker 3: be the the most it's I think we are going
- 12:27Speaker 3: to live in a time of uncertainty for the drug
- 12:29Speaker 3: supply chain until there's some clarity around. You know. Is
- 12:32Speaker 3: Tariff's a tool that the administration is proposing to generate
- 12:38Speaker 3: negotiation to land somewhere a little bit softer, landing somewhere
- 12:43Speaker 3: in the short term that then combines with either tax
- 12:47Speaker 3: incentives or other incentives that are used to bring more
- 12:52Speaker 3: production onto the US shore. But I certainly, you know,
- 12:56Speaker 3: hope that we don't end up in a position where
- 12:59Speaker 3: pharmacy continue to struggle, continue to fight challenges on reimbursement
- 13:04Speaker 3: and availability of products, and we're already seeing so many
- 13:09Speaker 3: pharmacies struggling today to just keep their head above water.
- 13:14Speaker 3: I don't see a lot of good here in the
- 13:16Speaker 3: short term. Unfortunately. I think it makes it even more
- 13:19Speaker 3: important than ever for pharmacies to optimize their cost of goods.
- 13:24Speaker 3: It's the one lever left that pharmacies really have any
- 13:28Speaker 3: control over it all. And so yeah, we will talk
- 13:32Speaker 3: a bit in a moment, I hope about about what
- 13:34Speaker 3: prim Marx is doing to help.
- 13:36Speaker 1: Absolutely, the next subject that I want to make sure
- 13:39Speaker 1: our listeners get some information from because this is going
- 13:43Speaker 1: to come up in their minds as they're listening, is
- 13:46Speaker 1: the shortages that this could create around chemotherapy, drugs and
- 13:50Speaker 1: pain relievers and antibiotics ADHD medications. Those are one of
- 13:55Speaker 1: the top seven that are listed right now that are
- 13:59Speaker 1: going through some shortage issues. Three hundred plus NDCs are
- 14:04Speaker 1: on the shortage lists. So when I think of the
- 14:08Speaker 1: tariff issue and impacts, it's going to be impacting our
- 14:13Speaker 1: shortage issues too. So definitely give us your thoughts on
- 14:17Speaker 1: shortages and accessibility.
- 14:20Speaker 3: Absolutely agree yes, Like I mentioned earlier, the pharmaceutical manufacturers
- 14:26Speaker 3: are not going to continue to produce drugs just for
- 14:29Speaker 3: the benefit of the US healthcare system. It has to
- 14:31Speaker 3: be financially rewarding for them to continue to produce those drugs.
- 14:35Speaker 3: And when they're not, then the easiest thing for them
- 14:38Speaker 3: to do is to shut down production lines and move
- 14:41Speaker 3: those production lines to more profitable drugs. That is in
- 14:46Speaker 3: large part what drives drug shortages in the environment we
- 14:50Speaker 3: already live in without tariffs. So tariffs, you know, essentially
- 14:55Speaker 3: raising the cost of production for pharmaceutical manufacturers in other
- 14:59Speaker 3: countries is going to have to lead to them shifting
- 15:02Speaker 3: those costs or discontinuing those product lines. And when you
- 15:08Speaker 3: know a major manufacturer or multiple major manufacturers of you know,
- 15:13Speaker 3: some of the top suspensed medications in the US stop
- 15:18Speaker 3: producing those drugs, they we don't have an easy place
- 15:21Speaker 3: to go to fill to backfill that supply. So I
- 15:26Speaker 3: do think that, unfortunately, drug shortages will continue to remain
- 15:31Speaker 3: at least at the level they're at now, and if
- 15:34Speaker 3: tariffs are implemented at the rate proposed, then they could
- 15:38Speaker 3: potentially become even much more of a problem grade grade.
- 15:44Speaker 1: So there's policy and regulations that we're going to be
- 15:46Speaker 1: waiting on to really gel and having to wait on something,
- 15:53Speaker 1: having to wait on PBM reform, or having to sit
- 15:56Speaker 1: around and wait for policy to kind of really becomes
- 16:01Speaker 1: something beyond the hyper boil that could be on either
- 16:04Speaker 1: side of the argument of good tariffs, bad tariffs, things
- 16:09Speaker 1: that we cannot control. David, Goodness, gracious, we can't control that.
- 16:13Speaker 1: But I love this speculation. I love the insights because
- 16:17Speaker 1: it's butted up against data and things that we have
- 16:20Speaker 1: to really dig down into for our pharmacy owner listeners.
- 16:24Speaker 1: But we do have control over something, and that's next.
- 16:29Speaker 1: So let's shift gears. We're talking about the tariffs and
- 16:33Speaker 1: the tariffs impact on my pharmacy business. They're my impact
- 16:36Speaker 1: on my accessibility for my patients to the medication on
- 16:40Speaker 1: the impact on pricing of profitability. Obviously, we can control
- 16:45Speaker 1: some things through market and that was the reason that
- 16:49Speaker 1: you came on the show originally in the first of
- 16:52Speaker 1: the year beginning of twenty twenty five. And now we
- 16:56Speaker 1: have more and more of our pharmacy owners engaging. You
- 17:02Speaker 1: have transactions to show that there is in fact an
- 17:05Speaker 1: impact on savings and on monthly savings. So let's shift
- 17:09Speaker 1: that gear and talk about what pharmacy pharmacy owners can
- 17:12Speaker 1: do right now that they are in control of through
- 17:15Speaker 1: the market system.
- 17:18Speaker 3: Yeah, thanks Todd and just I want our pharmacy owners
- 17:22Speaker 3: and operators to just think about the fact that within
- 17:27Speaker 3: the world of PBM dominated reimbursement for pharmaceuticals, pharmacy owners
- 17:34Speaker 3: don't have the ability to shift costs anywhere the reimbursement
- 17:39Speaker 3: is controlled by the terms of an agreement you have
- 17:42Speaker 3: with a PBM. When prices come down, reimbursement comes down.
- 17:46Speaker 3: It happens rather quickly, and you're you know, you're making
- 17:50Speaker 3: the same margin percentage on a smaller number, and your
- 17:55Speaker 3: profitability declines slightly as price comes down. On the other end,
- 17:59Speaker 3: pb have been notoriously slowed update reimbursement rates when prices rise,
- 18:05Speaker 3: and this leaves pharmacies exposed while their prices go up
- 18:09Speaker 3: and they're still being paid based on outdated price benchmarks.
- 18:13Speaker 3: So really, from my standpoint, the most important thing that
- 18:17Speaker 3: pharmacy operators can control is your cost of goods. It's
- 18:21Speaker 3: the most immediate actionable lever that you have. The era
- 18:26Speaker 3: of single supplier loyalty really has to come to an end.
- 18:30Speaker 3: Most pharmacies buy most of their drugs from a single source,
- 18:34Speaker 3: and that completely eliminates competition from driving prices in their favor.
- 18:41Speaker 3: Competition does drive savings. Diversification is really the only way
- 18:46Speaker 3: to stay agile while you're facing drug shortages or while
- 18:50Speaker 3: price volatility is impacting your business. We see pharmacies today
- 18:56Speaker 3: using primarx market. We've got fifty vetted wholesale in one
- 19:00Speaker 3: place that you can shop across. Those wholesalers. They come
- 19:04Speaker 3: onto our marketplace and they have to compete on price
- 19:08Speaker 3: and they have to compete on availability. And these are
- 19:11Speaker 3: the two biggest factors facing pharmacies in an uncertain time
- 19:15Speaker 3: with looming tariffs that you need to be in the
- 19:19Speaker 3: driver's seat. You have to control your own destiny and
- 19:21Speaker 3: not be reliant on macroeconomic changes that you can't control.
- 19:27Speaker 3: Pharmacies today are saving tens of thousands of dollars a year. Literally,
- 19:31Speaker 3: we have pharmacies saving hundreds of thousands of dollars a
- 19:34Speaker 3: year on their cost of goods just by shifting a
- 19:37Speaker 3: portion of their of their purchasing to a more competitive source.
- 19:42Speaker 3: And I think today it's time to adapt to doing
- 19:46Speaker 3: the things that we've always done in pharmacy, the way
- 19:48Speaker 3: we've always done them. It just is not working anymore.
- 19:51Speaker 3: The pharmacy that's going to continue to survive and thrive
- 19:54Speaker 3: in this uncertain marketplace that we operate in is the
- 19:58Speaker 3: one that adapts in real time. I'm drug by drug.
- 20:01Speaker 3: Adaptability is the way to control margin, and we're helping
- 20:05Speaker 3: pharmacies adapt and survive at primar X.
- 20:09Speaker 1: If you're listening, I just want you to pay attention.
- 20:11Speaker 1: There are links in your show notes, but if you
- 20:14Speaker 1: just want to type this in, if you're in front
- 20:16Speaker 1: of your desktop, just type in primearx dot io forward
- 20:20Speaker 1: slash market. Once again, that's primearx dot Io forward slash Market.
- 20:26Speaker 1: If you are driving or doing something, don't worry. The
- 20:29Speaker 1: link will be in the show notes. And David, what's
- 20:32Speaker 1: actionable is that means they can do this today. They
- 20:35Speaker 1: can set up an account, they can register under ten minutes.
- 20:38Speaker 1: It's easy to start making some comparisons and tell them
- 20:42Speaker 1: about the whopping cost of what this costs them to.
- 20:46Speaker 3: Yeah, it will cost you an enormous amount of zero
- 20:50Speaker 3: dollars to do the primar x marketplace. It is free
- 20:53Speaker 3: to our pharmacy buyers and absolutely provides immediate access to
- 21:00Speaker 3: like I said, almost fifty wholesalers, full line wholesalers, brands, Generics, OTCS,
- 21:08Speaker 3: controlled substances, medical devices, you name it. Mostly most of
- 21:14Speaker 3: the products that a pharmacy needs, either behind the counter
- 21:17Speaker 3: or over the counter, you're going to find on the market,
- 21:20Speaker 3: and you're going to find it competitively priced, and you're
- 21:23Speaker 3: going to find it in good supply from well known
- 21:26Speaker 3: trusted wholesalers.
- 21:29Speaker 1: David, I want to just say thank you on behalf
- 21:32Speaker 1: of our listeners and myself bringing us content that is
- 21:35Speaker 1: really not only updating and demystifying what is tariffs, how
- 21:41Speaker 1: are tariff's going to impact us, but giving us another
- 21:44Speaker 1: solution of another option of how to save some money
- 21:48Speaker 1: so that we can be profitable and not just surviving
- 21:51Speaker 1: but thriving as pharmacies. And it's harder than ever to
- 21:54Speaker 1: do so, but having tools like this is pretty important.
- 21:57Speaker 1: So thank you so much for being part of another podcast.
- 22:01Speaker 1: I don't know you're going to come back for the
- 22:02Speaker 1: triple for the triple hips.
- 22:04Speaker 3: Absolutely yeah, I'm happy to talk pharmacy with you anytime.
- 22:07Speaker 3: Todd Well, I love it.
- 22:08Speaker 1: You were listening to the Pharmacy podcast networks coverage of
- 22:13Speaker 1: trends in pharmacy with prim Rx. They've been a great
- 22:18Speaker 1: resource partner and really driving quality knowledge with the Pharmacy
- 22:23Speaker 1: Podcast Tech Trends, prescribing knowledge and dispensing wisdom in every episode.
- 22:28Speaker 1: Thank you so much for listening. Subscribe on all platforms, Spotify, Apple,
- 22:33Speaker 1: anything that you have for preface and take a look
- 22:36Speaker 1: at Primearx, dot Io, Forward Slash Podcasts for the entire library.
- 22:41Speaker 1: Once again, that's prime Rx, dot Io, Forward Slash Podcasts
- 22:46Speaker 1: and David, we will talk with you next time.
- 22:49Speaker 3: Thanks Tod.